ARCHIVES

FDA Ponders Standards For “Retrospective Prospective” Studies

This article is from The Cancer Letter archive.

Vol. 35 No. 04 | January 30, 2009

Download PDF Visit The Full Archive

Related Articles

In Brief: House, Senate Authorization Measuring Waiting Floor Action; Money Bill Markups Pending

June 13, 1980

Sprycell Approved for CML

November 5, 2010

Canadian Responds To Criticism Of Study, Says Results Not ‘Politically Correct’

November 27, 1992

Ann Landers, Columnist Who Urged Support for Cancer Act, Dead

June 28, 2002

FDA Approvals: Lymphoseek Label Updated to Include Head and Neck SCC

June 27, 2014

Nature Editorial Criticizes NCI PR Spending

March 15, 2013